Literature DB >> 16490554

Long-term central venous catheters: size and location do matter.

Raymond P Onders1, Robert R Shenk, Thomas A Stellato.   

Abstract

BACKGROUND: Right or left side of placement for subclavian vein catheterization for placement of long-term central catheters and size of the catheters has not been analyzed completely.
METHODS: The records of 502 consecutive long-term central venous catheters placed in patients while in the operating room over a 1-year period were reviewed and 230 subclavian vein tunneled catheters were analyzed. Technical difficulties in placing the catheters were defined as arterial puncture, guidewire malposition, catheter malposition, need to switch site of access, sheath difficulty, and inability to place the catheter.
RESULTS: Three complications were identified (1%) and technical difficulties occurred in 15% of the patients. More difficulty was associated with the insertion of larger triple-lumen catheters than smaller single-lumen catheters (31% vs. 11%, respectively; P < .009). Right subclavian placement was associated with a 24.4% technical difficulty rate versus a 10.4% technical difficulty rate for left subclavian placement (P < .005).
CONCLUSIONS: This study supports placing the smallest catheter necessary via the left subclavian vein.

Entities:  

Mesh:

Year:  2006        PMID: 16490554     DOI: 10.1016/j.amjsurg.2005.10.044

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  2 in total

1.  [Ultrasound-guided central venous access in adults and children: Procedure and pathological findings].

Authors:  P Scheiermann; F H Seeger; R Breitkreutz
Journal:  Anaesthesist       Date:  2010-01       Impact factor: 1.041

2.  Implanting totally implantable venous access port via the internal jugular vein guided by ultrasonography is feasible and safe in patients with breast cancer.

Authors:  Jie Zhou; Shikun Qian; Weixing He; Guodong Han; Hongsheng Li; Rongcheng Luo
Journal:  World J Surg Oncol       Date:  2014-12-08       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.